Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

UH Seidman is Actively Enrolling Patients in CAR-T Clinical Trials

Share
Facebook
Twitter
Pinterest
LinkedIn
Email
Print

UH Seidman Cancer Center Update | October 2019

By Paolo Caimi, MD


UH Seidman Cancer Center physicians are currently enrolling patients in the following two clinical trials:

CASE 2417 – Point of Care Manufactured AntiCD19 CAR-T Cells for Relapsed or Refractory Non Hodgkin’s Lymphoma

• This Phase I investigator-initiated trial evaluates the use of rapid, local manufacture of AntiCD19 CAR-T cells for the treatment of relapsed/refractory lymphomas. CAR-T cells are manufactured in the UH Seidman Cancer Center Cellular Therapy Lab for 8-12 days, allowing for treatment of patients who would otherwise not be able to wait for other cellular therapies  manufactured off-site.
• This trial is actively enrolling. Patients with CD19+ lymphomas who have failed two or more lines of therapy are eligible. 
ClinicalTrials.gov #NCT03434769

JUNO 1417 ¬– AntiCD19 CAR-T Cells for Treatment of Chronic Lymphocytic Leukemia

• This Phase I industry-based trial examines the safety and activity of anti CD19 CAR-T cells in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
• This study is actively enrolling. Eligible patients include: High risk CLL patients who have failed 2 lines of therapy or standard risk patients who have failed 3 lines of treatment. 

For more information on either of these trials call 216-844-3951.

Share
Facebook
Twitter
Pinterest
LinkedIn
Email
Print